MX2021011688A - Combinaciones utiles en un metodo para tratar sarcoma. - Google Patents
Combinaciones utiles en un metodo para tratar sarcoma.Info
- Publication number
- MX2021011688A MX2021011688A MX2021011688A MX2021011688A MX2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A
- Authority
- MX
- Mexico
- Prior art keywords
- treating sarcoma
- subject
- useful combinations
- sarcoma
- treating
- Prior art date
Links
- 206010039491 Sarcoma Diseases 0.000 title abstract 3
- -1 small molecule compound Chemical class 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825017P | 2019-03-27 | 2019-03-27 | |
| PCT/US2020/025532 WO2020198705A1 (en) | 2019-03-27 | 2020-03-27 | Combinations useful in a method for treating sarcoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011688A true MX2021011688A (es) | 2022-01-24 |
Family
ID=72609016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011688A MX2021011688A (es) | 2019-03-27 | 2020-03-27 | Combinaciones utiles en un metodo para tratar sarcoma. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220152024A1 (enExample) |
| EP (1) | EP3947379A4 (enExample) |
| JP (1) | JP7602481B2 (enExample) |
| CN (1) | CN114096537B (enExample) |
| AU (1) | AU2020248103A1 (enExample) |
| BR (1) | BR112021019170A2 (enExample) |
| CA (1) | CA3134648A1 (enExample) |
| EA (1) | EA202192349A1 (enExample) |
| IL (1) | IL286647A (enExample) |
| MX (1) | MX2021011688A (enExample) |
| WO (1) | WO2020198705A1 (enExample) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (enExample) * | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| EP1351691A4 (en) * | 2000-12-12 | 2005-06-22 | Cytovia Inc | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF |
| US20100297216A1 (en) * | 2006-12-20 | 2010-11-25 | Gabizon Alberto A | Method for administration of pegylated liposomal doxorubicin |
| KR20220143164A (ko) * | 2012-11-21 | 2022-10-24 | 피티씨 테라퓨틱스, 인크. | 치환된 리버스 피리미딘 bmi-1 저해제 |
| BR112021002630A2 (pt) * | 2018-08-17 | 2021-05-11 | Ptc Therapeutics, Inc. | método para tratar câncer pancreático |
| EA202192167A1 (ru) * | 2019-03-11 | 2022-01-12 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Форма соединения, обладающая повышенной биодоступностью, и ее составы |
-
2020
- 2020-03-27 CN CN202080039624.8A patent/CN114096537B/zh active Active
- 2020-03-27 EP EP20776386.3A patent/EP3947379A4/en active Pending
- 2020-03-27 EA EA202192349A patent/EA202192349A1/ru unknown
- 2020-03-27 MX MX2021011688A patent/MX2021011688A/es unknown
- 2020-03-27 JP JP2021557396A patent/JP7602481B2/ja active Active
- 2020-03-27 AU AU2020248103A patent/AU2020248103A1/en not_active Abandoned
- 2020-03-27 US US17/441,355 patent/US20220152024A1/en not_active Abandoned
- 2020-03-27 WO PCT/US2020/025532 patent/WO2020198705A1/en not_active Ceased
- 2020-03-27 CA CA3134648A patent/CA3134648A1/en active Pending
- 2020-03-27 BR BR112021019170A patent/BR112021019170A2/pt not_active Application Discontinuation
-
2021
- 2021-09-23 IL IL286647A patent/IL286647A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021019170A2 (pt) | 2022-03-03 |
| US20220152024A1 (en) | 2022-05-19 |
| JP2022519930A (ja) | 2022-03-25 |
| EA202192349A1 (ru) | 2022-02-01 |
| CN114096537A (zh) | 2022-02-25 |
| EP3947379A1 (en) | 2022-02-09 |
| EP3947379A4 (en) | 2022-12-21 |
| JP7602481B2 (ja) | 2024-12-18 |
| CA3134648A1 (en) | 2020-10-01 |
| WO2020198705A1 (en) | 2020-10-01 |
| IL286647A (en) | 2021-10-31 |
| AU2020248103A1 (en) | 2021-10-21 |
| CN114096537B (zh) | 2025-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014548A (es) | Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1). | |
| DOP2019000266A (es) | Inhibidores de pd-1/pd-l1 | |
| CL2018002334A1 (es) | Moduladores de complementos factor b (divisional solicitud 201600606) | |
| EA201890749A1 (ru) | ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ | |
| CO2017010618A2 (es) | Anticuerpos contra icos | |
| EA201992177A1 (ru) | Композиции на основе нирапариба | |
| CL2017000507A1 (es) | Derivados de benzodiazepina citotóxicos | |
| CL2020003276A1 (es) | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias | |
| CL2019002797A1 (es) | Preservantes para madera. | |
| MX389499B (es) | Metodos, composiciones y usos relacionados con los mismos | |
| EA201792096A3 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| CL2021001922A1 (es) | Procedimientos para tratamiento de enfermedades con inhibidores de magl. | |
| MX2019003545A (es) | Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas. | |
| CO2021000087A2 (es) | Combinación de factor vii y de un anticuerpo biespecífico dirigido contra los factores ix y x | |
| UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
| CL2022001511A1 (es) | Procesos e intermediario para la preparación de oxetan-2-ilmetanamina | |
| MX2016002308A (es) | Tratamiento del mieloma multiple. | |
| MX2021011688A (es) | Combinaciones utiles en un metodo para tratar sarcoma. | |
| WO2020180842A3 (en) | Aptamers and use thereof | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| GB2543709A (en) | Pharmaceutical agent | |
| EA202192117A1 (ru) | Способ лечения множественной миеломы | |
| MX2021003496A (es) | Potenciacion del tratamiento contra helmintos. | |
| EA202091694A1 (ru) | Ингибиторы pd-1/pd-l1 | |
| CL2016002283A1 (es) | Uso de una composición que comprende por lo menos tres diferentes compuestos seleccionados del grupo que consiste de 5’-metilselenoadenosina, se-adenosil-l-homocisteína, gama-glutamil-metilseleno-cisteína, un compuesto de la fórmula (i), (ii) o (iii) definidas y un portador para tratar la diabetes; composición. |